MedTrace Logo

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

NCT01115855 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.

Conditions

Interventions

DRUG

Eplerenone

Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily

DRUG

Placebo

Placebo once daily or every once daily

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01115855 on ClinicalTrials.gov